Results 131 to 140 of about 476,712 (311)
Molecular Oncology, EarlyView.Small extracellular vesicles are a promising source of diagnostic molecules. We conducted a comprehensive study, including transcriptome profiling and RT‐qPCR validation on large cohorts of samples. Diagnostic panels enabling sensitive detection of colorectal cancer and precancerous lesions were established. Some molecules were differentially expressed
Petra Vychytilova‐Faltejskova +26 more
wiley +1 more source
Two Masters of Surgery in Parma during the Middle Ages. [PDF]
Acta Biomed, 2020 Cervellin G +3 more
europepmc +1 more source
Molecular Oncology, EarlyView.Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi +12 more
wiley +1 more source
Book Review: V. Church History: A History of Education during the Middle Ages and the Translation to Modern Times [PDF]
, 1911 W. J. McGlothlin
openalex +1 more source
Historicising stress: anguish and insomnia in the middle ages. [PDF]
Interface Focus, 2020 MacLehose W.
europepmc +1 more source
Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs
Molecular Oncology, EarlyView.In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza +3 more
wiley +1 more source
Book Review: VI. Miscellaneous: A History of Classical Scholarship from the Sixth Century B. C. to the End of the Middle Ages [PDF]
, 1907 A. T. Robertson
openalex +1 more source
Different Approach to Horses-The Use of Equid Remains in the Early Middle Ages on the Example of Ostrów Tumski in Wroclaw. [PDF]
Animals (Basel), 2020 Jaworski K +3 more
europepmc +1 more source
Molecular Oncology, EarlyView.PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source